Could posturography be a useful outcome measure for chronic inflammatory demyelinating polyneuropathy?

Affiliations

Editorial

Karissa L Gable et al. Muscle Nerve. 2022 Jan.

. 2022 Jan;65(1):7-9.

doi: 10.1002/mus.27438. Epub 2021 Oct 30.

No abstract available

Keywords: chronic inflammatory demyelinating polyneuropathy; efficacy; outcome measure.

Comment on

Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
Silsby M, Yiannikas C, Ng K, Kiernan MC, Fung VSC, Vucic S. Silsby M, et al. Muscle Nerve. 2022 Jan;65(1):43-50. doi: 10.1002/mus.27398. Epub 2021 Aug 24. Muscle Nerve. 2022. PMID: 34383335

1. Lunn MP, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry. 1999;66(5):677-680.
1. Laughlin RS, Dyck PJ, Melton LJ 3rd, et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73(1):39-45.
1. Allen JA, Butler L, Levine T, Haudrich A. A global survey of disease burden in patients who carry a diagnosis of chronic inflammatory Demylenating polyneuropathy. Adv Ther. 2021;38:316-328.
1. Ryltoft AK, Al-Zuhairy A, Sindrup SH, Andersen H, Markvardsen LK. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin. Acta Neurol Scand. 2020;142:637-640.
1. Venkataraman K, Tai BC, Khoo EYH, et al. Short-term strength and balance training does not improve quality of life but improves functional status in individuals with diabetic peripheral neuropathy: a randomised controlled trial. Diabetologia. 2019;62(12):2200-2210.